Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F Fuller

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Cancer|September 26, 2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumorsR T Penson, J G Supko, M V Seiden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 1984
Sarcomas of the uterine corpus: prognostic factors and treatmentD S Shimm, D A Bell, A F Fuller, et al.
Cancer|September 15, 1984
Low-dose preoperative radiation therapy for adenocarcinoma of the endometrium. A pilot studyC C Wang, D S Shimm, D E Dosoretz, et al.
Gynecologic Oncology|March 1, 1996
Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III diseaseB A Goff, R Sainz de la Cuesta, H G Muntz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MISP T Masiakos, D T MacLaughlin, S Maheswaran, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxelR. T. Penson, K. Kronish, Z. Duan, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Cancer|September 26, 2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumorsR T Penson, J G Supko, M V Seiden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 1984
Sarcomas of the uterine corpus: prognostic factors and treatmentD S Shimm, D A Bell, A F Fuller, et al.
Cancer|September 15, 1984
Low-dose preoperative radiation therapy for adenocarcinoma of the endometrium. A pilot studyC C Wang, D S Shimm, D E Dosoretz, et al.
Gynecologic Oncology|March 1, 1996
Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III diseaseB A Goff, R Sainz de la Cuesta, H G Muntz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MISP T Masiakos, D T MacLaughlin, S Maheswaran, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxelR. T. Penson, K. Kronish, Z. Duan, et al.
Pageof 8